Literature DB >> 21890453

The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma.

Luca Agnelli1, Mattia Forcato, Francesco Ferrari, Giacomo Tuana, Katia Todoerti, Brian A Walker, Gareth J Morgan, Luigia Lombardi, Silvio Bicciato, Antonino Neri.   

Abstract

PURPOSE: The combined use of microarray technologies and bioinformatics analysis has improved our understanding of biological complexity of multiple myeloma (MM). In contrast, the application of the same technology in the attempt to predict clinical outcome has been less successful with the identification of heterogeneous molecular signatures. Herein, we have reconstructed gene regulatory networks in a panel of 1,883 samples from MM patients derived from publicly available gene expression sets, to allow the identification of robust and reproducible signatures associated with poor prognosis across independent data sets. EXPERIMENTAL
DESIGN: Gene regulatory networks were reconstructed by using Algorithm for the Reconstruction of Accurate Cellular Networks (ARACNe) and microarray data from seven MM data sets. Critical analysis of network components was applied to identify genes playing an essential role in transcriptional networks, which are conserved between data sets.
RESULTS: Network critical analysis revealed that (i) CCND1 and CCND2 were the most critical genes; (ii) CCND2, AIF1, and BLNK had the largest number of connections shared among the data sets; (iii) robust gene signatures with prognostic power were derived from the most critical transcripts and from shared primary neighbors of the most connected nodes. Specifically, a critical-gene model, comprising FAM53B, KIF21B, WHSC1, and TMPO, and a neighbor-gene model, comprising BLNK shared neighbors CSGALNACT1 and SLC7A7, predicted survival in all data sets with follow-up information.
CONCLUSIONS: The reconstruction of gene regulatory networks in a large panel of MM tumors defined robust and reproducible signatures with prognostic importance, and may lead to identify novel molecular mechanisms central to MM biology. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21890453     DOI: 10.1158/1078-0432.CCR-11-0596

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  28 in total

1.  Overexpression of SLC7A7 predicts poor progression-free and overall survival in patients with glioblastoma.

Authors:  Songhua Fan; Delong Meng; Tao Xu; Yuanyuan Chen; Jingkun Wang; Xiaoying Li; Hongyan Chen; Daru Lu; Juxiang Chen; Qing Lan
Journal:  Med Oncol       Date:  2013-02-14       Impact factor: 3.064

Review 2.  Neural model of gene regulatory network: a survey on supportive meta-heuristics.

Authors:  Surama Biswas; Sriyankar Acharyya
Journal:  Theory Biosci       Date:  2016-04-05       Impact factor: 1.919

3.  Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.

Authors:  Simona Blotta; Jana Jakubikova; Teresa Calimeri; Aldo M Roccaro; Nicola Amodio; Abdel Kareem Azab; Umberto Foresta; Constantine S Mitsiades; Marco Rossi; Katia Todoerti; Stefano Molica; Fortunato Morabito; Antonino Neri; Piersandro Tagliaferri; Pierfrancesco Tassone; Kenneth C Anderson; Nikhil C Munshi
Journal:  Blood       Date:  2012-07-20       Impact factor: 22.113

4.  RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma.

Authors:  Robert C Smallridge; Ana-Maria Chindris; Yan W Asmann; John D Casler; Daniel J Serie; Honey V Reddi; Kendall W Cradic; Michael Rivera; Stefan K Grebe; Brian M Necela; Norman L Eberhardt; Jennifer M Carr; Bryan McIver; John A Copland; E Aubrey Thompson
Journal:  J Clin Endocrinol Metab       Date:  2013-12-02       Impact factor: 5.958

5.  Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1.

Authors:  Teresa S Hawley; Irene Riz; Wenjing Yang; Yoshiyuki Wakabayashi; Louis Depalma; Young-Tae Chang; Weiqun Peng; Jun Zhu; Robert G Hawley
Journal:  Am J Hematol       Date:  2013-03-08       Impact factor: 10.047

6.  Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.

Authors:  P Storti; V Marchica; I Airoldi; G Donofrio; E Fiorini; V Ferri; D Guasco; K Todoerti; R Silbermann; J L Anderson; W Zhao; L Agnelli; M Bolzoni; E Martella; C Mancini; N Campanini; D M Noonan; P G Petronini; A Neri; F Aversa; G D Roodman; N Giuliani
Journal:  Leukemia       Date:  2016-05-20       Impact factor: 11.528

Review 7.  Lamina-associated polypeptide (LAP)2α and other LEM proteins in cancer biology.

Authors:  Andreas Brachner; Roland Foisner
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

8.  Comparison of microarray expression profiles between follicular variant of papillary thyroid carcinomas and follicular adenomas of the thyroid.

Authors:  Hans-Juergen Schulten; Zuhoor Al-Mansouri; Ibtisam Baghallab; Nadia Bagatian; Ohoud Subhi; Sajjad Karim; Hosam Al-Aradati; Abdulmonem Al-Mutawa; Adel Johary; Abdulrahman A Meccawy; Khalid Al-Ghamdi; Osman Al-Hamour; Mohammad Hussain Al-Qahtani; Jaudah Al-Maghrabi
Journal:  BMC Genomics       Date:  2015-01-15       Impact factor: 3.969

9.  Drug metabolism and clearance system in tumor cells of patients with multiple myeloma.

Authors:  Wafa Hassen; Alboukadel Kassambara; Thierry Reme; Surinder Sahota; Anja Seckinger; Laure Vincent; Guillaume Cartron; Jérôme Moreaux; Dirk Hose; Bernard Klein
Journal:  Oncotarget       Date:  2015-03-20

10.  Genetic program activity delineates risk, relapse, and therapy responsiveness in multiple myeloma.

Authors:  Matthew A Wall; Serdar Turkarslan; Wei-Ju Wu; Samuel A Danziger; David J Reiss; Mike J Mason; Andrew P Dervan; Matthew W B Trotter; Douglas Bassett; Robert M Hershberg; Adrián López García de Lomana; Alexander V Ratushny; Nitin S Baliga
Journal:  NPJ Precis Oncol       Date:  2021-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.